Similar articles

• Pharmacokinetics of hexamethylmelamine and pentamethylmelamine in mice.

  Broggini M, Colombo T, D'Incalci M, Donnelli MG, Gescher A, Garattini S. Broggini M, et al. Cancer Treat Rep. 1981 Jul-Aug;65(7-8):669-72. Cancer Treat Rep. 1981. PMID: 6788370
• Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma.

  Garattini E, Colombo T, Donelli MG, Catalani P, Bianchi M, D'Incalci M, Pantarotto C. Garattini E, et al. Cancer Chemother Pharmacol. 1983;11(1):51-5. doi: 10.1007/BF00257418. Cancer Chemother Pharmacol. 1983. PMID: 6411375
• Biochemical studies on the ability of pentamethylmelamine to interact in vivo with DNA and proteins in a sensitive murine ovarian reticular cell sarcoma.

  Garattini E, Broggini M, Coccia P, Colombo T, Rossi C, D'Incalci M. Garattini E, et al. Biochem Pharmacol. 1984 Sep 1;33(17):2715-22. doi: 10.1016/0006-2952(84)90686-5. Biochem Pharmacol. 1984. PMID: 6431992
• Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?

  Foster BJ, Clagett-Carr K, Marsoni S, Simon R, Leyland-Jones B. Foster BJ, et al. Cancer Treat Rep. 1986 Aug;70(8):1003-14. Cancer Treat Rep. 1986. PMID: 3089597 Review.
• Hexamethylmelamine: a critical review of an active drug.

  Foster BJ, Harding BJ, Leyland-Jones B, Hoth D. Foster BJ, et al. Cancer Treat Rev. 1986 Dec;13(4):197-217. doi: 10.1016/0305-7372(86)90006-x. Cancer Treat Rev. 1986. PMID: 3102057 Review.